BioXcel Therapeutics Inc.

09/05/2024 | Press release | Distributed by Public on 09/05/2024 05:07

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.